Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -1-
June 21, 2004
- Tokushukai Group Plans Clinical Trials via Its Network
June 21, 2004
- BUSINESS NEWS IN BRIEF -2-
June 21, 2004
- Large-scale Study Started on Antihypertensive Combination Therapy: Jikei Univ. Group
June 21, 2004
- 5 NCEs Including Octreotide to Be Included in NHI List
June 21, 2004
- Large-Scale Study on Mosapride in Functional Dyspepsia Starts
June 21, 2004
- Chuikyo Members Call For Revision of Drug Pricing Rules
June 21, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
June 21, 2004
- WORLD NEWS IN BRIEF
June 14, 2004
- OTC NEWS IN BRIEF
June 14, 2004
- Listed Makers Report Decline in Sales, Strong Increase in Net Profits on Non-consolidated Basis
June 14, 2004
- Annual Business Results
June 14, 2004
- Wakamoto: Ethical Drug Sales Fall 3% to \6.5 Bil.
June 14, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 14, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
June 14, 2004
- DIAGNOSTIC NEWS IN BRIEF
June 14, 2004
- SEMIANNUAL SALES
June 14, 2004
- New Drugs Prolong Longevity by 3 Weeks Per Year: Dr Lichtenberg
June 14, 2004
- BULLETIN
June 14, 2004
- MR-Kun Service Could Begin This Autumn in the US: So-net M3
June 14, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…